This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inogen (INGN) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Inogen (INGN) reports impressive Q4 financial results on the back of strong business-to-business and direct-to-consumer sales growth.
Healthcare, Vertex to Drive 3D Systems (DDD) Q4 Earnings?
by Zacks Equity Research
Strong prospects in 3D Systems' (DDD) healthcare business and Vertex brand are likely to prove conductive to its profitability in the to-be-reported quarter.
Is a Beat in Store for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.
Inogen (INGN) Gains on Diverse Product Line, Competition Rife
by Zacks Equity Research
Inogen (INGN) rides on POC growth. Existing market challenges likely to mar prospects.
Can CVG Boost Medtronic's (MDT) Q3 Earnings Once Again?
by Zacks Equity Research
New therapies within CVG should help Medtronic???s (MDT) Q3 gain traction in the rapidly growing markets for LVAD, TAVR, drug-coated balloons, atrial fibrillation and insertable diagnostics.
Inogen Rides on Solid Product Portfolio Amid Forex Woes
by Zacks Equity Research
Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.
Inogen Claims Top Position in Deloitte List on Solid Growth
by Zacks Equity Research
Inogen's (INGN) unique direct-to-customer business model has lent it a leading position in the United States.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.
McKesson (MCK) to Acquire RxCrossroads for $735 Million
by Zacks Equity Research
McKesson's (MCK) acquisition of RxCrossroads will boost its Specialty Health business.
Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Inogen (INGN) develops, manufactures and markets POCs. The company's direct-to-customer business model lent it a leading position in the oxygen therapy space.
Inogen (INGN) Down 2.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights: SP Plus, Inogen, Graco, Sterling Construction and FireEye
by Zacks Equity Research
Zacks.com featured highlights: SP Plus, Inogen, Graco, Sterling Construction and FireEye
5 Stocks to Beat the Market This Reporting Cycle
by Zacks Equity Research
Inside the stocks that are likely to beat earnings estimates in their upcoming releases.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.
Myriad Genetics to Grow with Study Successes, New Alliances
by Zacks Equity Research
On Jul 6, we issued an updated research report on Myriad Genetics, Inc. (MYGN).
Medtronic (MDT) Launches Resolute Onyx DES Device in Japan
by Zacks Equity Research
Medtronic plc (MDT), a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest revenue grossing Cardiovascular segment.
Thermo Fisher at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Thermo Fisher Scientific Inc. (TMO), headquartered in Waltham, MA, scaled a new 52-week high of $177.99 on Jul 7, eventually closing a shade lower at $177.49.
Investors Look for Gains as Abbott Labs Set to Acquire Alere
by Zacks Equity Research
On majority of Alere shareholders' recent approval in favor of the merger with Abbott (ABT), the deal is now expected to close by the end of third-quarter 2017.
Zacks Industry Outlook Highlights: Varian Medical Systems, Inogen, Edwards Lifesciences, Orthofix International and INSYS Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Varian Medical Systems, Inogen, Edwards Lifesciences, Orthofix International and INSYS Therapeutics
ResMed Sees Potential in SDB Market, Eyes Global Growth
by Zacks Equity Research
On Jul 6, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).
Baxter and TAU Ink New Licensing Agreements through Ramot
by Zacks Equity Research
Baxter International (BAX) has recently teamed up with Tel Aviv University, Israel's largest research and teaching university (TAU), on two new licensing agreements through Ramot.
Mazor Expects Higher Q2 Revenues, Wins Mazor X Orders
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it expects to report second-quarter 2017 revenue of approximately $15.4 million compared with $8.3 million from the year-ago quarter.
Phibro Animal Health & Zydus Cadila Plan to Expand in India
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) recently announced plans to enter into a long-term agreement with global pharmaceutical company Zydus Cadila to expand in the rapidly growing poultry market in India.
Edwards Lifesciences' INSPIRIS RESILIA Valve Wins FDA Nod
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) recently announced the receipt of FDA approval for its INSPIRIS RESILIA aortic valve.
Will Walgreens Gain from Revised Rite Aid Agreement?
by Zacks Equity Research
The new agreement would enable Walgreens Boots Alliance (WBA) to buy nearly half of the Rite Aid business at a deal value, almost one-third of the original price.